CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions-A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).
Meeting Abstract
Bendell, Johanna C.; Lim, Kian-Huat; Burkard, Mark E.; Klempner, Samuel J.; Socinski, Mark A.; Gadgeel, Shirish M.; Reckamp, Karen L.; Leland, Shawn Michael; Plessinger, Doug; Kunkel, Lori A.; Dotan, Efrat; Otterson, Gregory Alan; Ou, Sai-Hong Ignatius; Patil, Tejas; Heymach, John; Kim, Edward S.